Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new therapy offers hopeful perspectives for patients suffering from spondyloarthropathy

07.03.2002


Spondyloarthropathies are rheumatic infectious diseases affecting the spinal column and peripheral joints and tendons. These diseases either occur as such (Bechterew`s disease or ankylosing spondylitis), or are combined with skin psoriasis, inflammatory intestinal diseases (Crohn`s disease and ulcerating colitis), and eye infection (uveitis).

These diseases effect about 1% of total world population and often develop into seriously debilitating conditions with complete stiffening of the spinal column and destruction of the peripheral joints (hips, knees, wrists and/or fingers). Thus far, treatment of these diseases has been limited to the administration of non-steroid anti-inflammatory drugs, which may have a benevolent effect on the subjective complaints of pain, but does not effect the evolution of the disease.

Tumor Necrosis Factor is a small molecule (a cytokine) which is released by the disposal cells (macrophages) of the immune systems at sites where the inflammation occurs and which, in case of spondyloarthropathy, induces changes in the bone, joints and tendons.


Two years ago the Department of Rheumatology of the University of Ghent, Belgium, initiated an open study involving the treatment of 21 patients suffering from various forms of these diseases with intravenous injections of a monoclonal antibody targeting the Tumor Nacrosis Factor (Infliximab). The results were impressive not only with regard to the complaints, but also with regard to the symptoms of infection of the spinal column and the peripheral sites, and the infection factors measured in the blood. These results were confirmed in a double blind study involving 40 other patients, the data that were published in the March 6, 2002 issue of Arthritis and Rheumatology, the leading scientific journal in the area of rheumatology.

The conclusion of the study can be summarized as follows. The authors report the successful results of a double-blind placebo-controlled study with Infliximab on several sub-types of spondyloarthropathies. For the first time, we have an effective therapeutic option for severe cases. Long-term results (more than 1 year) of patients treated in the initial open study were already disclosed in a previous publication. The future of patients suffering from spondyloarthropathy is hopeful. It seems as if all requirements have been met to allow us to hope that this treatment will be able to prevent the stiffening of the spinal column and the destruction of the peripheral joints, and that the quality of life of these patients will improve considerably.

Eric VEYS | alphagalileo

More articles from Health and Medicine:

nachricht Radioisotope couple for tumor diagnosis and therapy
14.05.2019 | Kanazawa University

nachricht Therapy Optimisation by Analysing the Genome
13.05.2019 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Discovering unusual structures from exception using big data and machine learning techniques

17.05.2019 | Materials Sciences

ALMA discovers aluminum around young star

17.05.2019 | Physics and Astronomy

A new iron-based superconductor stabilized by inter-block charger transfer

17.05.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>